학술논문
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Document Type
Article
Author
Drew, Y.; Kim, J.-W.; Penson, R.T.; O’Malley, D.M.; Parkinson, C.; Roxburgh, P.; Plummer, R.; Im, S.-A.; Imbimbo, M.; Ferguson, M.; Rosengarten, O.; Steeghs, N.; Kim, M.H.; Gal-Yam, E.; Tsoref, D.; Kim, J.-H.; You, B.; De Jonge, M.; Lalisang, R.; Gort, E.; Bastian, S.; Meyer, K.; Feeney, L.; Baker, N.; Ah-See, M.-L.; Domchek, S.M.; Banerjee, S.
Source
In: Clinical Cancer Research . (Clinical Cancer Research, 10 January 2024, 30(1):50-62)
Subject
Language
English
ISSN
15573265
10780432
10780432